New Findings Demonstrate Technological Advances for Extending Serum Half-Life of Drugs Bound to Albumin
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced new data on extending the serum half-life of albumin in vivo.
This compelling data set, recently presented at PepTalk 2014, demonstrates the potential of the company's half-life extension platform to deliver greater control of the therapeutic half-life of drug candidates, while showing how the technology can introduce the possibility for monthly dosing.
"This data represents the most promising insight yet that Novozymes' half-life extension technology delivers the reduction in dosing frequency that we set out to deliver when we began developing the platform 5 years ago," comments Dermot Pearson, Marketing Director at Novozymes Biopharma.
He continues: "The level of excitement expressed by our customers in response to these achievements has been exceptional and we look forward to sharing our latest findings with wider industry experts who can benefit from this leading-edge data."
Through the modification of the human albumin molecule, Novozymes has altered the affinity of albumin to the FcRn receptor and has been able to demonstrate extended serum half-life of a range of albumin variants in vivo. The innovative technology provides drug developers with an attractive approach for optimizing the serum half-life of biopharmaceuticals. Already demonstrated in the fields of diabetes, hemophilia and neutropenia, the platform offers the potential to enhance patient quality of life through tailoring drug circulatory half-life to meet specific medical needs, while contributing improvements in compliance and healthcare costs.
A presentation on the new data can be downloaded from the posters and presentation section in the Information Centre at www.biopharma.novozymes.com
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance